Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

被引：4
|
作者：
Duerr, Donat [1 ]
Siciliano, Raffaele Daniele [1 ]
Hummel, Yvonne [1 ]
O'Meara, Alix [1 ]
Hirschi, Anita [1 ]
Burkhard, Roger [1 ]
Honegger, Hanspeter [1 ]
机构：
[1] Stadtspital Triemli, CH-8063 Zurich, Switzerland
来源：
ANNALS OF HEMATOLOGY | 2010年 / 89卷 / 01期
关键词：
DELETION; MANAGEMENT; DEL(5Q);
D O I：
10.1007/s00277-009-0775-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [21] TELOMERE SHORTENING AND AML PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q TREATED WITH LENALIDOMIDE
    Goehring, G.
    Lange, K.
    Hofmann, W.
    Buesche, G.
    Kreipe, H.
    Hellstroem-Lindberg, E.
    Giagounidis, A.
    Schlegelberger, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 378 - 379
  • [22] Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
    Serin, Istemi
    Eren, Rafet
    Dogu, Mehmet Hilmi
    JOURNAL OF HEMATOLOGY, 2020, 9 (1-2) : 33 - 36
  • [23] Efficacy of lenalidomide for treatment of anemia in secondary myelodysplastic syndrome (MDS) with chromosome 5q deletion
    Mintzer, David Michael
    Billet, Shira N.
    BLOOD, 2007, 110 (11) : 226B - 226B
  • [24] Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q)
    Adema, Vera
    Palomo, Laura
    Fuster-Tormo, Francisco
    Benito, Rocio
    Salgado, Rocio
    Such, Esperanza
    Kosmider, Olivier
    Larrayoz, Maria Jose
    Xicoy, Blanca
    Janusz, Kamila
    Maietta, Paolo
    Neef, Alexander
    Amunchastegui, Beatriz Arrizabalaga
    Fontenay, Michaela
    Gomez-Marzo, Paula
    Del Rey, Monica
    Ibanez, Mariam
    Haro, Nuri
    Mallo, Mar
    Zamora, Lurdes
    Visconte, Valeria
    Maciejewski, Jaroslaw P.
    Fenaux, Pierre
    Cervera, Jose
    Calasanz, Maria Jose
    Hernandez-Rivas, Jesus Maria
    Cigudosa, Juan
    Sole, Francesc
    BLOOD, 2016, 128 (22)
  • [25] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    BMC Cancer, 15
  • [26] Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Schmidt, Aline
    Visanica, Sorin
    Eclache, Virginie
    Turlure, Pascal
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Rea, Delphine
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2011, 35 (11) : 1444 - 1448
  • [27] MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
    Martinez-Hoyer, Sergio
    Deng, Yu
    Parker, Jeremy
    Jiang, Jihong
    Docking, Roderick
    Mo, Angela
    Gharaee, Nadia
    Jadersten, Martin
    Kulasekararaj, Austin
    Malcovati, Luca
    List, Alan
    Hellstrom-Lindberg, Eva
    Platzbecker, Uwe
    Karsan, Aly
    EXPERIMENTAL HEMATOLOGY, 2020, 88 : S72 - S72
  • [28] Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
    Omar A. Alkharabsheh
    Salwa S. Saadeh
    Darci L. Zblewski
    Naseema Gangat
    Kebede H. Begna
    Michelle A. Elliott
    Hassan B. Alkhateeb
    Mrinal S. Patnaik
    William J. Hogan
    Mark R. Litzow
    Aref Al-Kali
    Annals of Hematology, 2019, 98 : 331 - 337
  • [29] Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
    Alkharabsheh, Omar A.
    Saadeh, Salwa S.
    Zblewski, Darci L.
    Gangat, Naseema
    Begna, Kebede H.
    Elliott, Michelle A.
    Alkhateeb, Hassan B.
    Patnaik, Mrinal S.
    Hogan, William J.
    Litzow, Mark R.
    Al-Kali, Aref
    ANNALS OF HEMATOLOGY, 2019, 98 (02) : 331 - 337
  • [30] Health and economic impact of the discontinuation of lenalidomide treatment in patients with myelodysplastic syndrome associated with del(5q)
    Alarcon-Payer, C.
    Salazar Bravo, M.
    Jimenez Morales, A.
    Garcia Fumero, R.
    Jurado Chacon, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 380 - 380
12345